Prevention of venous thromboembolism
122 results
1 - 100
Statins for the primary prevention of venous thromboembolism- Thrombophilia testing for prevention of recurrent venous thromboembolism
- Neuromuscular electrical stimulation for the prevention of venous thromboembolism
- Secondary prevention of recurrent venous thromboembolism after initial oral anticoagulation therapy in patients with unprovoked venous thromboembolism
- Interventions for preventing venous thromboembolism following abdominal aortic surgery
- Interventions for the primary prevention of venous thromboembolism for hip fracture surgery
- Pentasaccharides for the prevention of venous thromboembolism: Cochrane systematic review
- Statins for primary prevention of venous thromboembolism: Cochrane systematic review
- Pharmacological interventions for preventing venous thromboembolism in people undergoing bariatric surgery
- Interventions for preventing venous thromboembolism in adults undergoing knee arthroscopy
- Low molecular weight heparin for prevention of venous thromboembolism in patients with lower‐limb immobilization
- Combined intermittent pneumatic leg compression and pharmacological prophylaxis for prevention of venous thromboembolism
- Different types of intermittent pneumatic compression devices for preventing venous thromboembolism in patients after total hip replacement
- Continuous passive motion for preventing venous thromboembolism after total knee arthroplasty: Cochrane systematic review
- Heparin for the prevention of venous thromboembolism in acutely ill medical patients (excluding stroke and myocardial infarction): Cochrane systematic review
- Direct thrombin inhibitors versus vitamin K antagonists or low molecular weight heparins for prevention of venous thromboembolism following total hip or knee replacement
- Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
- Direct factor Xa inhibitors versus low molecular weight heparins or vitamin K antagonists for prevention of venous thromboembolism in elective primary hip or knee replacement or hip fracture repair
- Primary prophylaxis for venous thromboembolism in patients undergoing cardiac or thoracic surgery
- Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism: Cochrane systematic review
- Warfarin initiation nomograms for venous thromboembolism: Cochrane systematic review
- Subcutaneous unfractionated heparin for the initial treatment of venous thromboembolism
- Primary prophylaxis for venous thromboembolism in people undergoing major amputation of the lower extremity
- Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
- Standard‐ versus extended‐duration anticoagulation for primary venous thromboembolism prophylaxis in acutely ill medical patients
- Hormone therapy for preventing cardiovascular disease in post‐menopausal women
- Vitamin K antagonists versus low‐molecular‐weight heparin for the long term treatment of symptomatic venous thromboembolism
- Long‐term hormone therapy for perimenopausal and postmenopausal women
- Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for the initial treatment of venous thromboembolism
- Venous thromboembolism prophylaxis for women at risk during pregnancy and the early postnatal period
- Interventions for implementation of thromboprophylaxis in hospitalized patients at risk for venous thromboembolism
- Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome
- Unfractionated heparin versus low molecular weight heparins for avoiding heparin‐induced thrombocytopenia in postoperative patients
- Heparins and mechanical methods for thromboprophylaxis in colorectal surgery
- Prophylactic anticoagulants for non‐hospitalised people with COVID‐19
- Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss
- Semi‐recumbent position versus supine position for the prevention of ventilator‐associated pneumonia in adults requiring mechanical ventilation
- Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the treatment of pulmonary embolism
- Endovenous ablation for venous leg ulcers
- Low‐molecular‐weight heparins or heparinoids versus standard unfractionated heparin for acute ischaemic stroke
- Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia
- Graduated compression stockings for prevention of deep vein thrombosis
- Strontium ranelate for preventing and treating postmenopausal osteoporosis
- Methods for administering subcutaneous heparin during pregnancy
- Treatment for superficial thrombophlebitis of the leg
- Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the treatment of deep vein thrombosis
- Oral anticoagulation in people with cancer who have no therapeutic or prophylactic indication for anticoagulation
- Effect of testing for cancer on cancer‐ or venous thromboembolism (VTE)‐related mortality and morbidity in people with unprovoked VTE